COMMUNIQUÉS West-GlobeNewswire

argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
01/05/2025
May 1, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it [...]
Hydreight Achieves Record Revenue and Profitability Milestone in Q4 2024 Audited Results
01/05/2025
Record 2024 Topline¹ revenue of $22.32 million, up 31% from 2023 Record 2024 GAAP revenue of $16.04 million, up 39% from 2023 2024 Adjusted EBITDA¹ of +490K compared to ($1.38) million in 2023 2024 gross margin of $5.75 [...]
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC
01/05/2025
OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology TAIPEI, Taiwan, May 01, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (“OBI”), a clinical stage oncology company（4174.TWO), today [...]
SurgiBox Announces Strategic Partnership with BestBrick Medical in Taiwan
01/05/2025
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- SurgiBox, Inc., a pioneering medical technology company dedicated to bringing safe surgery to every patient, today announced a strategic partnership with BestBrick [...]
Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia
01/05/2025
NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine For more information, please read [...]
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
01/05/2025
Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney disease with no FDA- [...]
Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations
01/05/2025
Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces the appointment of Shinya Tsuzuki, as Head of Investor Relations. Mr. Tsuzuki will lead Nxera’s [...]
UPDATE – The International Myeloma Foundation Mourns the Loss of Board Member and Longtime Philanthropist John O’Dwyer
01/05/2025
STUDIO CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Today, the International Myeloma Foundation (IMF) announced with great sadness, the passing of one of the IMF’s Board Members and longtime philanthropist John O’ [...]
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
01/05/2025
Cincinnati, OH, April 30, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on April 24, 2025 [...]
AdCare Hospital Names New Executive Director to Tackle Growing Addiction Crisis Across Massachusetts
30/04/2025
WORCESTER, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- As Massachusetts continues to see waves of preventable deaths from the opioid overdose epidemic, AdCare Hospital, a longstanding provider of addiction treatment [...]
Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
30/04/2025
NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra [...]
New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity
30/04/2025
Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to forgo sentinel lymph [...]
LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025
30/04/2025
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the [...]
Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference
30/04/2025
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free [...]
Best CBD Gummies of 2025: Cornbread Hemp CBD Products Help with Sleep, Pain, and Stress Relief
30/04/2025
Award-winning CBD gummies for sleep, stress, and sleep with organic full-spectrum formulations in flavors like berry, watermelon, strawberry, and blood orange. Louisville, KY, April 30, 2025 (GLOBE NEWSWIRE) -- In a [...]
CooperCompanies Appoints Barbara Carbone to Board of Directors
30/04/2025
SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent [...]
Teladoc Health Reports First Quarter 2025 Results
30/04/2025
PURCHASE, NY, April 30, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended March 31, 2025 (“First Quarter 2025”). [...]
Scorpius Holdings Provides 2024 Year-End Business Update; Implements Strategic Cost Reductions and Operational Streamlining
30/04/2025
SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO”), today provided strategic, [...]
Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025
30/04/2025
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]

Pages